<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/>
  <meta name="type" content="article"/>
  <meta name="category" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/01/30/2020.01.28.922922.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.01.28.922922v2"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening"/>
  <meta name="DC.Identifier" content="10.1101/2020.01.28.922922"/>
  <meta name="DC.Date" content="2020-01-30"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="© 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission."/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of the outbreak of pneumonia first detected in Wuhan, China. Investigations on the transmissibility, severity, and other features associated with this virus are ongoing. Currently, there is no vaccine or therapeutic antibody to prevent the infection, and more time is required to develop an effective immune strategy against the pathogen. In contrast, specific inhibitors targeting the key protease involved in replication and proliferation of the virus are the most effective means to alleviate the epidemic. The main protease of SARS-CoV is essential for the life cycle of the virus, which showed 96.1% of similarity with the main proteaseof 2019-nCoV, is considered to be an attractive target for drug development. In this study, we have identified 4 small molecular drugs with high binding capacity with SARS-CoV main protease by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of 2019-nCoV."/>
  <meta name="DC.Contributor" content="Yan Li"/>
  <meta name="DC.Contributor" content="Jinyong Zhang"/>
  <meta name="DC.Contributor" content="Ning Wang"/>
  <meta name="DC.Contributor" content="Haibo Li"/>
  <meta name="DC.Contributor" content="Yun Shi"/>
  <meta name="DC.Contributor" content="Gang Guo"/>
  <meta name="DC.Contributor" content="Kaiyun Liu"/>
  <meta name="DC.Contributor" content="Hao Zeng"/>
  <meta name="DC.Contributor" content="Quanming Zou"/>
  <meta name="article:published_time" content="2020-01-30"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening"/>
  <meta name="citation_abstract" lang="en" content="&lt;;h3&gt;;Abstract&lt;;/h3&gt;; &lt;;p&gt;;2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of the outbreak of pneumonia first detected in Wuhan, China. Investigations on the transmissibility, severity, and other features associated with this virus are ongoing. Currently, there is no vaccine or therapeutic antibody to prevent the infection, and more time is required to develop an effective immune strategy against the pathogen. In contrast, specific inhibitors targeting the key protease involved in replication and proliferation of the virus are the most effective means to alleviate the epidemic. The main protease of SARS-CoV is essential for the life cycle of the virus, which showed 96.1% of similarity with the main proteaseof 2019-nCoV, is considered to be an attractive target for drug development. In this study, we have identified 4 small molecular drugs with high binding capacity with SARS-CoV main protease by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of 2019-nCoV.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.01.28.922922v2"/>
  <meta name="citation_id" content="2020.01.28.922922v2"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.01.28.922922v2"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.01.28.922922v2.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.01.28.922922v2.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.01.28.922922"/>
  <meta name="citation_num_pages" content="16"/>
  <meta name="citation_article_type" content="Article"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.01.28.922922"/>
  <meta name="citation_author" content="Yan Li"/>
  <meta name="citation_author_institution" content="West China Biopharm Research Institute, West China Hospital, Sichuan University"/>
  <meta name="citation_author" content="Jinyong Zhang"/>
  <meta name="citation_author_institution" content="National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University"/>
  <meta name="citation_author" content="Ning Wang"/>
  <meta name="citation_author_institution" content="West China Biopharm Research Institute, West China Hospital, Sichuan University"/>
  <meta name="citation_author" content="Haibo Li"/>
  <meta name="citation_author_institution" content="National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University"/>
  <meta name="citation_author" content="Yun Shi"/>
  <meta name="citation_author_institution" content="West China Biopharm Research Institute, West China Hospital, Sichuan University"/>
  <meta name="citation_author" content="Gang Guo"/>
  <meta name="citation_author_institution" content="West China Biopharm Research Institute, West China Hospital, Sichuan University"/>
  <meta name="citation_author" content="Kaiyun Liu"/>
  <meta name="citation_author_institution" content="West China Biopharm Research Institute, West China Hospital, Sichuan University"/>
  <meta name="citation_author" content="Hao Zeng"/>
  <meta name="citation_author_institution" content="National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University"/>
  <meta name="citation_author_email" content="zeng1109@163.com"/>
  <meta name="citation_author_email" content="qmzou2007@163.com"/>
  <meta name="citation_author" content="Quanming Zou"/>
  <meta name="citation_author_institution" content="National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University"/>
  <meta name="citation_author_email" content="zeng1109@163.com"/>
  <meta name="citation_author_email" content="qmzou2007@163.com"/>
  <meta name="citation_reference" content="Hui DS, E Ia, Madani TA, Ntoumi F, Kock R, et al. (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 91: 264–266."/>
  <meta name="citation_reference" content="Zhu N, Zhang D, Wang W, Li X, Yang B, et al. (2020) A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med."/>
  <meta name="citation_reference" content="Cooke FJ, Shapiro DS (2003) Global outbreak of severe acute respiratory syndrome (SARS). Int J Infect Dis 7: 80–85."/>
  <meta name="citation_reference" content="Xia B, Kang X (2011) Activation and maturation of SARS-CoV main protease. Protein Cell 2: 282–290."/>
  <meta name="citation_reference" content="Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, et al. (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46: D1074–D1082."/>
  <meta name="citation_reference" content="Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455–461."/>
  <meta name="citation_reference" content="Janson G, Zhang C, Prado MG, Paiardini A (2017) PyMod 2.0: improvements in protein sequence-structure analysis and homology modeling within PyMOL. Bioinformatics 33: 444–446."/>
  <meta name="citation_reference" content="Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, et al. (2020) Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv: 2020.2001.2022.914952."/>
  <meta name="citation_reference" content="Zhang D, Chen J, Deng L, Mao Q, Zheng J, et al. (2010) Evolutionary selection associated with the multi-function of overlapping genes in the hepatitis B virus. Infect Genet Evol 10: 84–88."/>
  <meta name="citation_reference" content="Fritsche TR, Biedenbach DJ, Jones RN (2009) Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler’s diarrhea. Antimicrob Agents Chemother 53: 1221–1224."/>
  <meta name="citation_reference" content="Matera MG (2006) Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 19 Suppl 1: 20–29."/>
  <meta name="citation_reference" content="Hebner CM, Han B, Brendza KM, Nash M, Sulfab M, et al. (2012) The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One 7: e39163."/>
  <meta name="citation_reference" content="Davis DA, Soule EE, Davidoff KS, Daniels SI, Naiman NE, et al. (2012) Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing. Antimicrob Agents Chemother 56: 3620–3628."/>
  <meta name="citation_reference" content="Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, et al. (2016) Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother 60: 7086–7097."/>
  <meta name="twitter:title" content="Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of the outbreak of pneumonia first detected in Wuhan, China. Investigations on the transmissibility, severity, and other features associated with this virus are ongoing. Currently, there is no vaccine or therapeutic antibody to prevent the infection, and more time is required to develop an effective immune strategy against the pathogen. In contrast, specific inhibitors targeting the key protease involved in replication and proliferation of the virus are the most effective means to alleviate the epidemic. The main protease of SARS-CoV is essential for the life cycle of the virus, which showed 96.1% of similarity with the main proteaseof 2019-nCoV, is considered to be an attractive target for drug development. In this study, we have identified 4 small molecular drugs with high binding capacity with SARS-CoV main protease by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of 2019-nCoV."/>
  <meta name="og-title" property="og:title" content="Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.01.28.922922v2"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of the outbreak of pneumonia first detected in Wuhan, China. Investigations on the transmissibility, severity, and other features associated with this virus are ongoing. Currently, there is no vaccine or therapeutic antibody to prevent the infection, and more time is required to develop an effective immune strategy against the pathogen. In contrast, specific inhibitors targeting the key protease involved in replication and proliferation of the virus are the most effective means to alleviate the epidemic. The main protease of SARS-CoV is essential for the life cycle of the virus, which showed 96.1% of similarity with the main proteaseof 2019-nCoV, is considered to be an attractive target for drug development. In this study, we have identified 4 small molecular drugs with high binding capacity with SARS-CoV main protease by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of 2019-nCoV."/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-01-30"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1127308 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-type-article hw-article-category-new-results"> 
  <div class="article fulltext-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2 class="">Abstract</h2>
    <p id="p-3">2019 Novel Coronavirus (2019-nCoV) is a virus identified as the cause of the outbreak of pneumonia first detected in Wuhan, China. Investigations on the transmissibility, severity, and other features associated with this virus are ongoing. Currently, there is no vaccine or therapeutic antibody to prevent the infection, and more time is required to develop an effective immune strategy against the pathogen. In contrast, specific inhibitors targeting the key protease involved in replication and proliferation of the virus are the most effective means to alleviate the epidemic. The main protease of SARS-CoV is essential for the life cycle of the virus, which showed 96.1% of similarity with the main proteaseof 2019-nCoV, is considered to be an attractive target for drug development. In this study, we have identified 4 small molecular drugs with high binding capacity with SARS-CoV main protease by high-throughput screening based on the 8,000 clinical drug libraries, all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of 2019-nCoV.</p>
   </div>
   <div class="section" id="sec-1">
    <h2 class="">1. Introduction</h2>
    <p id="p-4">Since December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, China. Genome sequencing of samples from these patients confirmed that the culprit of these infections was a beta-coronavirus that has never been reported before, which was later named as 2019-nCoV [
     <a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>,
     <a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>]. By Jan 28, 2020, more than 4500 patients were confirmed to be infected with 2019-nCoV, and nearly 100 patients were died from the infection. So far, the infection keeps spreading and more and more exported cases were confirmed in other provinces in China, and several other countries, including the United States, posing great pressure on public health security.
    </p>
    <p id="p-5">The discovery and clinical application of specific drugs against 2019-nCoV is an effective means to alleviate the current epidemic. However, there are no clinically effective drugs for this virus for the moment. Although 2019-nCoV is significantly different from SARS-CoV, which breakout in Beijing 17 years before [
     <a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>], the sequence identity between themis as high as 79.5%. Further sequence alignment revealed that the similarity of the sequence of the main protease between 2019-nCoV and SARS-CoV is up to 96.1%. Previous study demonstrated that the main protease of SARS-CoV is essential for the life cycle of the virus, and is considered to be an attractive target for drug development [
     <a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>]. Thus, this protein could be used as a homologous target to screening drugs that inhibiting the replication and proliferation of 2019-nCoV.
    </p>
    <p id="p-6">In order to screening the possible drug candidates that were able to prevent or cure the infection, high-throughput screening was performed based on the 8,000 clinical drug libraries using the online software Vina and SeeSAR, combined with our in-house automatic processing scripts and screening programs, and 4 small molecular drugs with high binding capacity with SARS-CoV main protease were identified. These drugs were widely used in clinical practice, so the safety was guaranteed. In view of the activity and safety of these wildly used drugs, it is feasible to conduct clinical exploratory treatment in special cases such as the outbreak of 2019-nCoV. Here we report the identify and structure of these molecules.</p>
   </div>
   <div class="section" id="sec-2">
    <h2 class="">2. Material and Methods</h2>
    <div id="sec-3" class="subsection">
     <h3>2.1 Data resources</h3>
     <p id="p-7">The CDS and proteins of Wuhan seafood market pneumonia virus (Accession: 
      <a class="external-ref external-ref-type-gen" href="/lookup/external-ref?link_type=GEN&amp;;access_num=NC_045512.2&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom">NC_045512.2</a>) were obtained from NBCI database. The structures and sequences of SARS-CoV main protease were downloaded from PDB database. Nearly 8000 molecules were obtained from Drugbank [
      <a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>], including the approval or experimental compounds and small molecules
     </p>
    </div>
    <div id="sec-4" class="subsection">
     <h3>2.2 Similarity search</h3>
     <p id="p-8">Molecular similarity search was performed by using a strategy based on the similar sequences ofthe structure-revealed molecules. The NCBI-blast v2.9 was installed in local machine, then a local database was established by the molecular sequences of SARS-CoV main protease from PDB. The blastp was ran by default parameter.</p>
    </div>
    <div id="sec-5" class="subsection">
     <h3>2.3 Molecular docking</h3>
     <p id="p-9">The AutoDock vina was obtained from website of scripps.edu [
      <a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>]. The crystal structure of main protease monomer (PDB id: 5n5o) was used as target protein after removing the unrelated complex molecule by AutoDockTools. The receptor was prepared by removing water, adding hydrogen and computing charges. The binding coordinates were located by Grid box including the cave near N-terminal and the joint groove of dimer. Autodocking was performed by using multithread tasks by our in-house script, and potential molecules were screening out by a Perl program developed by us.
     </p>
    </div>
    <div id="sec-6" class="subsection">
     <h3>2.4 Protein-ligand interaction Analysis</h3>
     <p id="p-10">The candidates harvested from docking were deeply analyzed for atom-based affinity contributions and physical-chemical properties by SeeSAR (version 9.2; BioSolveIT GmbH, Sankt Augustin, Germany, 2019, 
      <a href="http://www.biosolveit.de/SeeSAR">www.biosolveit.de/SeeSAR</a>).
     </p>
    </div>
    <div id="sec-7" class="subsection">
     <h3>2.5 Structure Display</h3>
     <p id="p-11">The 3D molecule images were displayed by PyMOL v2.3 [
      <a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>].
     </p>
    </div>
    <div id="sec-8" class="subsection">
     <h3>2.6 Screening criteria</h3>
     <p id="p-12">The affinities of Vina less than −7.7 kcal/mol were harvested initially. Then those molecules were removed such as toxin, experimental and unapproved ones, and those with strong side effects. Finally, the candidate drugs were selected with better affinities in Vina and SeeSAR.</p>
    </div>
   </div>
   <div class="section" id="sec-9">
    <h2 class="">3. Results</h2>
    <div id="sec-10" class="subsection">
     <h3>3.1 Homologous targets screening</h3>
     <p id="p-13">We downloaded the sequences of a total of 103 SARS-CoV main proteases with different origins from PDB and built a local library for homology alignment. The result revealed that the similarity between the region at 3264 ∼ 3570 aa of 2019-nCoV ORF1 ab protein and SARS-CoV main protease 5n5o was up to 96.1% (
      <a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1</a>). Thus, the main protease is highly conserved and main protease 5n5ocan be used as a homologous target for screening of possible drugs against 2019-nCoV.
     </p>
     <div id="F1" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F1.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="The blast results of ORF1ab of 2019-nCoV against SARS-CoV main proteases." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-158631134" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;The blast results of ORF1ab of 2019-nCoV against SARS-CoV main proteases.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Fig. 1." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F1.medium.gif" width="348" height="440"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Fig. 1." src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F1.medium.gif" width="348" height="440"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F1.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 1." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F1.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Fig. 1.</span>
       <p id="p-14" class="first-child">The blast results of ORF1ab of 2019-nCoV against SARS-CoV main proteases.</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
    <div id="sec-11" class="subsection">
     <h3>3.2 Binding sites of target protein detection</h3>
     <p id="p-15">There were three binding pockets detected in the viral main protease by computation, as labeled in 
      <a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig.2C</a>. In comparison to the dimer and monomer structure of the protein (
      <a id="xref-fig-2-2" class="xref-fig" href="#F2">Fig.2A and B</a>), we could figure out that the pocket 1 was the binding site with natural substrate, pocket 2 was the joint groove between two monomers, and a small pocket 3 was located in the C terminal.
     </p>
     <div id="F2" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F2.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="Binding pockets and functional sites of SARS-CoV main protease A: Dimer structure; B: Monomer structure; C: Detected pockets." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-158631134" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;Binding pockets and functional sites of SARS-CoV main protease A: Dimer structure; B: Monomer structure; C: Detected pockets.&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Fig. 2." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F2.medium.gif" width="440" height="140"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Fig. 2." src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F2.medium.gif" width="440" height="140"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F2.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 2." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F2.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Fig. 2.</span>
       <p id="p-16" class="first-child">Binding pockets and functional sites of SARS-CoV main protease A: Dimer structure; B: Monomer structure; C: Detected pockets.</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
    <div id="sec-12" class="subsection">
     <h3>3.3 Candidates summary</h3>
     <p id="p-17">At first, we harvested 690 molecules with possible binding capacity with SARS-CoV main protease, but most of them were dyes, toxins and antitumor drugs with strong side effects, about 50 molecules were left after excluding these molecules and other neurologic drugs, and then we selected marketable drugs from them for further kinetic and bio-chemical analysis. Finally, 4 molecules were identified, including No. 6651 molecule (Prulifloxacin), No. 6589 molecule (Bictegravir), No. 0097 molecule (Nelfinavir) and No. 6626 molecule (Tegobuvi).</p>
    </div>
    <div id="sec-13" class="subsection">
     <h3>3.4 The interaction between Prulifloxacin and viral protease</h3>
     <p id="p-18">The binding energies of No. 6651 molecule (Prulifloxacin, 
      <a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 3A</a>) to viral main protease were −8.2 Kcal/mol, −8.2 Kcal/mol, −7.9 kcal/mol at three binding sites, respectively (
      <a id="xref-fig-3-2" class="xref-fig" href="#F3">Fig. 3B</a>), which were the cave adjacent to the N-terminal, the dimer joint groove and its back side. Moreover, at several docking poses, all of the estimated affinitiesof binding were between μM to mM. The evaluations of ligand-lipophilicity efficiency (LLE), torsion and clash were also satisfied.
     </p>
     <div id="F3" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F3.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="2D molecular structure of Prulifloxacin (A); Binding conformation of Prulifloxacin to viral protease (B); Physicochemical featureand affinity of Prulifloxacin to viral protease (C)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-158631134" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;2D molecular structure of Prulifloxacin (A); Binding conformation of Prulifloxacin to viral protease (B); Physicochemical featureand affinity of Prulifloxacin to viral protease (C).&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Fig.3." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F3.medium.gif" width="418" height="440"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Fig.3." src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F3.medium.gif" width="418" height="440"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F3.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig.3." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F3.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Fig.3.</span>
       <p id="p-19" class="first-child">2D molecular structure of Prulifloxacin (A); Binding conformation of Prulifloxacin to viral protease (B); Physicochemical featureand affinity of Prulifloxacin to viral protease (C).</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
    <div id="sec-14" class="subsection">
     <h3>3.5 The interaction between Bictegravir and main protease</h3>
     <p id="p-20">The binding sites between Bictegravir and the main protease was displayed at 
      <a id="xref-fig-4-1" class="xref-fig" href="#F4">Fig. 4B</a>, the binding energy between Bictegravir and major protease was −8.3 kcal/mol at the joint groove, but only −7.3 kcal/mol at the active site, and the estimated affinity is satisfied (
      <a id="xref-fig-4-2" class="xref-fig" href="#F4">Fig. 4C</a>).
     </p>
     <div id="F4" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F4.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="2D molecular structure of Bictegravir (A); Binding conformation of Bictegravir to viral protease (B); Physicochemical featureand affinity of Bictegravir to viral protease (C)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-158631134" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;2D molecular structure of Bictegravir (A); Binding conformation of Bictegravir to viral protease (B); Physicochemical featureand affinity of Bictegravir to viral protease (C).&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Fig. 4." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F4.medium.gif" width="440" height="341"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Fig. 4." src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F4.medium.gif" width="440" height="341"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F4.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 4." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F4.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Fig. 4.</span>
       <p id="p-21" class="first-child">2D molecular structure of Bictegravir (A); Binding conformation of Bictegravir to viral protease (B); Physicochemical featureand affinity of Bictegravir to viral protease (C).</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
    <div id="sec-15" class="subsection">
     <h3>3.6 The interaction between Nlfinavir and main protease</h3>
     <p id="p-22">The results showed that the binding site between Nelfinavir and the main protease was located at the joint groove (
      <a id="xref-fig-5-1" class="xref-fig" href="#F5">Fig. 5B</a>). The binding energy between Nelfinavir and major protease was −8.6 kcal/mol, but the estimated affinity seemed not high enough (
      <a id="xref-fig-5-2" class="xref-fig" href="#F5">Fig. 5C</a>).
     </p>
     <div id="F5" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F5.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="2D molecular structure of Nelfinavir (A); Binding conformation of Nelfinavir to viral protease (B); Physicochemical feature and affinity of Nelfinavir to viral protease (C)." class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-158631134" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;2D molecular structure of Nelfinavir (A); Binding conformation of Nelfinavir to viral protease (B); Physicochemical feature and affinity of Nelfinavir to viral protease (C).&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Fig. 5." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F5.medium.gif" width="440" height="271"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Fig. 5." src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F5.medium.gif" width="440" height="271"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F5.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig. 5." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F5.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Fig. 5.</span>
       <p id="p-23" class="first-child">2D molecular structure of Nelfinavir (A); Binding conformation of Nelfinavir to viral protease (B); Physicochemical feature and affinity of Nelfinavir to viral protease (C).</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
    <div id="sec-16" class="subsection">
     <h3>3.7 The interaction between Tegobuvir and main protease</h3>
     <p id="p-24">Tegobuvir was docked into the joint groove of main protein, the binding energy between them was −8.9 kcal/mol, and the estimated affinity is satisfied (
      <a id="xref-fig-6-1" class="xref-fig" href="#F6">Fig. 6C</a>). The binding sites was displayed at 
      <a id="xref-fig-6-2" class="xref-fig" href="#F6">Fig. 6B</a>.
     </p>
     <div id="F6" class="fig pos-float type-figure odd">
      <div class="highwire-figure">
       <div class="fig-inline-img-wrapper">
        <div class="fig-inline-img">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F6.large.jpg?width=800&amp;;height=600&amp;;carousel=1" title="2D molecular structure of Tegobuvir (A); Binding conformation of Tegobuvir to viral protease (B); Physicochemical feature and affinity of Tegobuvir to viral protease (C)" class="highwire-fragment fragment-images colorbox-load" rel="gallery-fragment-images-158631134" data-figure-caption="&lt;;div class=&quot;;highwire-markup&quot;;&gt;;2D molecular structure of Tegobuvir (A); Binding conformation of Tegobuvir to viral protease (B); Physicochemical feature and affinity of Tegobuvir to viral protease (C)&lt;;/div&gt;;" data-icon-position="" data-hide-link-title="0">
          <span class="hw-responsive-img">
           <img class="highwire-fragment fragment-image lazyload" alt="Fig.6." src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" data-src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F6.medium.gif" width="440" height="355"/>
           <noscript>
            <img class="highwire-fragment fragment-image" alt="Fig.6." src="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F6.medium.gif" width="440" height="355"/>
           </noscript>
          </span>
         </a>
        </div>
       </div>
       <ul class="highwire-figure-links inline">
        <li class="download-fig first">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F6.large.jpg?download=true" class="highwire-figure-link highwire-figure-link-download" title="Download Fig.6." data-icon-position="" data-hide-link-title="0">Download figure</a>
        </li>
        <li class="new-tab last">
         <a href="https://www.biorxiv.org/content/biorxiv/early/2020/01/30/2020.01.28.922922/F6.large.jpg" class="highwire-figure-link highwire-figure-link-newtab" target="_blank" data-icon-position="" data-hide-link-title="0">Open in new tab</a>
        </li>
       </ul>
      </div>
      <div class="fig-caption">
       <span class="fig-label">Fig.6.</span>
       <p id="p-25" class="first-child">2D molecular structure of Tegobuvir (A); Binding conformation of Tegobuvir to viral protease (B); Physicochemical feature and affinity of Tegobuvir to viral protease (C)</p>
       <div class="sb-div caption-clear"/>
      </div>
     </div>
    </div>
   </div>
   <div class="section" id="sec-17">
    <h2 class="">4. Discussion</h2>
    <p id="p-26">Although coronaviruses are under extensive mutagenesis, some key proteins, especially replication-related enzymes, are highly conserved [
     <a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>]. Because the mutation in key proteins are often lethal to the virus [
     <a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>], drugs that target conservative protease are usually capable of preventing the replication and proliferation of the virus and exhibit broad spectrum. Besides, they can reduce the risk of mutation mediated drug-resistance.
    </p>
    <p id="p-27">In the current study, based on the results from bioinformatics analysis, the structure of SARS-CoV 5n5o protein was selected as a homologous target for molecule screening. Then, in silico high throughput screening strategy and automatic pipeline have been established by using classic docking software and our in-house program, which greatly accelerates the screening process.</p>
    <p id="p-28">Among the four molecules identified in this study, Prulifloxacin is a chemotherapeutic fluoroquinolone antibiotic with broad-spectrum activity, it has been approved for the treatment of uncomplicated and complicated urinary tract infections, community-acquired respiratory tract infections in Italy and gastroenteritis, including infectious diarrheas, in Japan [
     <a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>]. Unfortunately, Prulifloxacin is reported as a prodrug, which is rapidly metabolized to ulifloxacin 
     <em>in vivo</em> [
     <a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>]. But it can be used as a lead compound that provide guidance for our later structural modification and optimization to design more effective main protease inhibitors. Tegobuvir is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection [
     <a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>]. In addition, both of Nelfinavir and Bictegravir are anti-HIV drugs, of which Nelfinavir is a protease Inhibitors inhibit the cleavage of the polyprotein gag-pol [
     <a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>], whereas Bictegravir is a new and potent HIV-1 integrase inhibitor, which is able to efficiently prevent HIV from multiplying and can reduce the amount of HIV in the body [
     <a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>].
    </p>
    <p id="p-29">Our results clearly showed that all the four molecules showed reasonable binding conformations with the viral main protease. Among them, Prulifloxacin exhibited three binding sites with main protease, two of which were the same as Nelfinavir and Bictegravir. Further, molecule Prulifloxacin, Tegobuvir and Bictegravir are preferable to Nelfinaviras confirmed by affinity and physical-chemical properties analysis using SeeSAR. Based on the pockets’ functions of target protein, it suggested that these molecules should possess the abilities to block the active sites or interrupt the dimer formation of viral protein. Therefore, they may sever as promising candidates for drug repurpose and development against 2019-nCoV.</p>
   </div>
   <div class="section ref-list" id="ref-list-1">
    <h2 class="">Reference</h2>
    <ol class="cit-list ref-use-labels">
     <li>
      <span class="ref-label">1.</span>
      <a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text" id="ref-1">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.1" data-doi="10.1016/j.ijid.2020.01.009">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Hui</span>
          <span class="cit-name-given-names">DS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-given-names">E</span>
          <span class="cit-name-surname">Ia</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Madani</span>
          <span class="cit-name-given-names">TA</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Ntoumi</span>
          <span class="cit-name-given-names">F</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kock</span>
          <span class="cit-name-given-names">R</span>
         </span>, 
         <span class="cit-etal">et al.</span> (
         <span class="cit-pub-date">2020</span>) 
         <span class="cit-article-title">The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China</span>. 
         <abbr class="cit-jnl-abbrev">Int J Infect Dis</abbr>
         <span class="cit-vol">91</span>: 
         <span class="cit-fpage">264</span>–
         <span class="cit-lpage">266</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DInt%2BJ%2BInfect%2BDis%26rft.volume%253D91%26rft.spage%253D264%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ijid.2020.01.009%26rft_id%253Dinfo%253Apmid%252F31953166%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/j.ijid.2020.01.009&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=31953166&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">2.</span>
      <a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2. in text" id="ref-2">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.2">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Zhu</span>
          <span class="cit-name-given-names">N</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>
          <span class="cit-name-given-names">D</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wang</span>
          <span class="cit-name-given-names">W</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Li</span>
          <span class="cit-name-given-names">X</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Yang</span>
          <span class="cit-name-given-names">B</span>
         </span>, 
         <span class="cit-etal">et al.</span> (
         <span class="cit-pub-date">2020</span>) 
         <span class="cit-article-title">A Novel Coronavirus from Patients with Pneumonia in China, 2019</span>. 
         <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>.
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">3.</span>
      <a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3. in text" id="ref-3">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.3" data-doi="10.1016/S1201-9712(03)90001-4">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Cooke</span>
          <span class="cit-name-given-names">FJ</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Shapiro</span>
          <span class="cit-name-given-names">DS</span>
         </span> (
         <span class="cit-pub-date">2003</span>) 
         <span class="cit-article-title">Global outbreak of severe acute respiratory syndrome (SARS)</span>. 
         <abbr class="cit-jnl-abbrev">Int J Infect Dis</abbr>
         <span class="cit-vol">7</span>: 
         <span class="cit-fpage">80</span>–
         <span class="cit-lpage">85</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DInternational%2Bjournal%2Bof%2Binfectious%2Bdiseases%2B%253A%2B%2BIJID%2B%253A%2Bofficial%2Bpublication%2Bof%2Bthe%2BInternational%2BSociety%2Bfor%2BInfectious%2BDiseases%26rft.stitle%253DInt%2BJ%2BInfect%2BDis%26rft.aulast%253DCooke%26rft.auinit1%253DF.%2BJ.%26rft.volume%253D7%26rft.issue%253D2%26rft.spage%253D80%26rft.epage%253D85%26rft.atitle%253DGlobal%2Boutbreak%2Bof%2Bsevere%2Bacute%2Brespiratory%2Bsyndrome%2B%2528SARS%2529.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1201-9712%252803%252990001-4%26rft_id%253Dinfo%253Apmid%252F12839707%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/S1201-9712(03)90001-4&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=12839707&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">4.</span>
      <a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4. in text" id="ref-4">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.4" data-doi="10.1007/s13238-011-1034-1">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Xia</span>
          <span class="cit-name-given-names">B</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Kang</span>
          <span class="cit-name-given-names">X</span>
         </span> (
         <span class="cit-pub-date">2011</span>) 
         <span class="cit-article-title">Activation and maturation of SARS-CoV main protease</span>. 
         <abbr class="cit-jnl-abbrev">Protein Cell</abbr>
         <span class="cit-vol">2</span>: 
         <span class="cit-fpage">282</span>–
         <span class="cit-lpage">290</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.stitle%253DProtein%2BCell%26rft.aulast%253DXia%26rft.auinit1%253DB.%26rft.volume%253D2%26rft.issue%253D4%26rft.spage%253D282%26rft.epage%253D290%26rft.atitle%253DActivation%2Band%2Bmaturation%2Bof%2BSARS-CoV%2Bmain%2Bprotease.%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs13238-011-1034-1%26rft_id%253Dinfo%253Apmid%252F21533772%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1007/s13238-011-1034-1&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=21533772&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">5.</span>
      <a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5. in text" id="ref-5">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.5" data-doi="10.1093/nar/gkx1037">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Wishart</span>
          <span class="cit-name-given-names">DS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Feunang</span>
          <span class="cit-name-given-names">YD</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Guo</span>
          <span class="cit-name-given-names">AC</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Lo</span>
          <span class="cit-name-given-names">EJ</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Marcu</span>
          <span class="cit-name-given-names">A</span>
         </span>, 
         <span class="cit-etal">et al.</span> (
         <span class="cit-pub-date">2018</span>) 
         <span class="cit-article-title">DrugBank 5.0: a major update to the DrugBank database for 2018</span>. 
         <abbr class="cit-jnl-abbrev">Nucleic Acids Res</abbr>
         <span class="cit-vol">46</span>: 
         <span class="cit-fpage">D1074</span>–
         <span class="cit-lpage">D1082</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DNucleic%2BAcids%2BRes%26rft.volume%253D46%26rft.spage%253DD1074%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fnar%252Fgkx1037%26rft_id%253Dinfo%253Apmid%252FPMC5753335%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1093/nar/gkx1037&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=PMC5753335&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">6.</span>
      <a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6. in text" id="ref-6">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.6" data-doi="10.1002/jcc.21334">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Trott</span>
          <span class="cit-name-given-names">O</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Olson</span>
          <span class="cit-name-given-names">AJ</span>
         </span> (
         <span class="cit-pub-date">2010</span>) 
         <span class="cit-article-title">AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span>. 
         <abbr class="cit-jnl-abbrev">J Comput Chem</abbr>
         <span class="cit-vol">31</span>: 
         <span class="cit-fpage">455</span>–
         <span class="cit-lpage">461</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bcomputational%2Bchemistry%26rft.stitle%253DJ%2BComput%2BChem%26rft.aulast%253DTrott%26rft.auinit1%253DO.%26rft.volume%253D31%26rft.issue%253D2%26rft.spage%253D455%26rft.epage%253D461%26rft.atitle%253DAutoDock%2BVina%253A%2Bimproving%2Bthe%2Bspeed%2Band%2Baccuracy%2Bof%2Bdocking%2Bwith%2Ba%2Bnew%2Bscoring%2Bfunction%252C%2Befficient%2Boptimization%252C%2Band%2Bmultithreading.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fjcc.21334%26rft_id%253Dinfo%253Apmid%252F19499576%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1002/jcc.21334&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=19499576&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000273412900020&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">7.</span>
      <a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text" id="ref-7">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.7" data-doi="10.1093/bioinformatics/btw638">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Janson</span>
          <span class="cit-name-given-names">G</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>
          <span class="cit-name-given-names">C</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Prado</span>
          <span class="cit-name-given-names">MG</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Paiardini</span>
          <span class="cit-name-given-names">A</span>
         </span> (
         <span class="cit-pub-date">2017</span>) 
         <span class="cit-article-title">PyMod 2.0: improvements in protein sequence-structure analysis and homology modeling within PyMOL</span>. 
         <abbr class="cit-jnl-abbrev">Bioinformatics</abbr>
         <span class="cit-vol">33</span>: 
         <span class="cit-fpage">444</span>–
         <span class="cit-lpage">446</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DBioinformatics%26rft.volume%253D33%26rft.spage%253D444%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fbioinformatics%252Fbtw638%26rft_id%253Dinfo%253Apmid%252F28158668%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1093/bioinformatics/btw638&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=28158668&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">8.</span>
      <a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text" id="ref-8">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.8">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Zhou</span>
          <span class="cit-name-given-names">P</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Yang</span>
          <span class="cit-name-given-names">X-L</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Wang</span>
          <span class="cit-name-given-names">X-G</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Hu</span>
          <span class="cit-name-given-names">B</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>
          <span class="cit-name-given-names">L</span>
         </span>, 
         <span class="cit-etal">et al.</span> (
         <span class="cit-pub-date">2020</span>) 
         <span class="cit-article-title">Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin</span>. 
         <abbr class="cit-jnl-abbrev">bioRxiv: 2020.2001.2022.914952</abbr>.
        </cite>
       </div>
       <div class="cit-extra"/>
      </div>
     </li>
     <li>
      <span class="ref-label">9.</span>
      <a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text" id="ref-9">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.9" data-doi="10.1016/j.meegid.2009.10.006">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Zhang</span>
          <span class="cit-name-given-names">D</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Chen</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Deng</span>
          <span class="cit-name-given-names">L</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Mao</span>
          <span class="cit-name-given-names">Q</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Zheng</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-etal">et al.</span> (
         <span class="cit-pub-date">2010</span>) 
         <span class="cit-article-title">Evolutionary selection associated with the multi-function of overlapping genes in the hepatitis B virus</span>. 
         <abbr class="cit-jnl-abbrev">Infect Genet Evol</abbr>
         <span class="cit-vol">10</span>: 
         <span class="cit-fpage">84</span>–
         <span class="cit-lpage">88</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DInfection%252C%2Bgenetics%2Band%2Bevolution%2B%253A%2B%2Bjournal%2Bof%2Bmolecular%2Bepidemiology%2Band%2Bevolutionary%2Bgenetics%2Bin%2Binfectious%2Bdiseases%26rft.stitle%253DInfect%2BGenet%2BEvol%26rft.aulast%253DZhang%26rft.auinit1%253DD.%26rft.volume%253D10%26rft.issue%253D1%26rft.spage%253D84%26rft.epage%253D88%26rft.atitle%253DEvolutionary%2Bselection%2Bassociated%2Bwith%2Bthe%2Bmulti-function%2Bof%2Boverlapping%2Bgenes%2Bin%2Bthe%2Bhepatitis%2BB%2Bvirus.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.meegid.2009.10.006%26rft_id%253Dinfo%253Apmid%252F19879378%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/j.meegid.2009.10.006&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=19879378&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">10.</span>
      <a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text" id="ref-10">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.10" data-doi="10.1128/AAC.01260-08">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Fritsche</span>
          <span class="cit-name-given-names">TR</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Biedenbach</span>
          <span class="cit-name-given-names">DJ</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Jones</span>
          <span class="cit-name-given-names">RN</span>
         </span> (
         <span class="cit-pub-date">2009</span>) 
         <span class="cit-article-title">Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler’s diarrhea</span>. 
         <abbr class="cit-jnl-abbrev">Antimicrob Agents Chemother</abbr>
         <span class="cit-vol">53</span>: 
         <span class="cit-fpage">1221</span>–
         <span class="cit-lpage">1224</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntimicrob%2BAgents%2BChemother%26rft_id%253Dinfo%253Adoi%252F10.1128%252FAAC.01260-08%26rft_id%253Dinfo%253Apmid%252F19114678%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYWFjIjtzOjU6InJlc2lkIjtzOjk6IjUzLzMvMTIyMSI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzAxLzMwLzIwMjAuMDEuMjguOTIyOTIyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">11.</span>
      <a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text" id="ref-11">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.11" data-doi="10.1016/j.pupt.2005.09.009">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Matera</span>
          <span class="cit-name-given-names">MG</span>
         </span> (
         <span class="cit-pub-date">2006</span>) 
         <span class="cit-article-title">Pharmacologic characteristics of prulifloxacin</span>. 
         <abbr class="cit-jnl-abbrev">Pulm Pharmacol Ther</abbr>
         <span class="cit-vol">19</span>
         <span class="cit-issue">Suppl 1</span>: 
         <span class="cit-fpage">20</span>–
         <span class="cit-lpage">29</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DPulm%2BPharmacol%2BTher%26rft.volume%253D19%26rft.spage%253D20%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.pupt.2005.09.009%26rft_id%253Dinfo%253Apmid%252F16360331%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1016/j.pupt.2005.09.009&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=16360331&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
        <a href="/lookup/external-ref?access_num=000235529000004&amp;;link_type=ISI" class="cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience">
         <span>Web of Science</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">12.</span>
      <a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text" id="ref-12">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.12" data-doi="10.1371/journal.pone.0039163">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Hebner</span>
          <span class="cit-name-given-names">CM</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Han</span>
          <span class="cit-name-given-names">B</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Brendza</span>
          <span class="cit-name-given-names">KM</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Nash</span>
          <span class="cit-name-given-names">M</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Sulfab</span>
          <span class="cit-name-given-names">M</span>
         </span>, 
         <span class="cit-etal">et al.</span> (
         <span class="cit-pub-date">2012</span>) 
         <span class="cit-article-title">The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function</span>. 
         <abbr class="cit-jnl-abbrev">PLoS One</abbr>
         <span class="cit-vol">7</span>: 
         <span class="cit-fpage">e39163</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.stitle%253DPLoS%2BONE%26rft.aulast%253DHebner%26rft.auinit1%253DC.%2BM.%26rft.volume%253D7%26rft.issue%253D6%26rft.spage%253De39163%26rft.epage%253De39163%26rft.atitle%253DThe%2BHCV%2Bnon-nucleoside%2Binhibitor%2BTegobuvir%2Butilizes%2Ba%2Bnovel%2Bmechanism%2Bof%2Baction%2Bto%2Binhibit%2BNS5B%2Bpolymerase%2Bfunction.%26rft_id%253Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0039163%26rft_id%253Dinfo%253Apmid%252F22720059%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/external-ref?access_num=10.1371/journal.pone.0039163&amp;;link_type=DOI" class="cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref">
         <span>CrossRef</span>
        </a>
        <a href="/lookup/external-ref?access_num=22720059&amp;;link_type=MED&amp;;atom=%2Fbiorxiv%2Fearly%2F2020%2F01%2F30%2F2020.01.28.922922.atom" class="cit-ref-sprinkles cit-ref-sprinkles-medline">
         <span>PubMed</span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">13.</span>
      <a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text" id="ref-13">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.13" data-doi="10.1128/AAC.00055-12">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Davis</span>
          <span class="cit-name-given-names">DA</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Soule</span>
          <span class="cit-name-given-names">EE</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Davidoff</span>
          <span class="cit-name-given-names">KS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Daniels</span>
          <span class="cit-name-given-names">SI</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Naiman</span>
          <span class="cit-name-given-names">NE</span>
         </span>, 
         <span class="cit-etal">et al.</span> (
         <span class="cit-pub-date">2012</span>) 
         <span class="cit-article-title">Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing</span>. 
         <abbr class="cit-jnl-abbrev">Antimicrob Agents Chemother</abbr>
         <span class="cit-vol">56</span>: 
         <span class="cit-fpage">3620</span>–
         <span class="cit-lpage">3628</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntimicrob%2BAgents%2BChemother%26rft_id%253Dinfo%253Adoi%252F10.1128%252FAAC.00055-12%26rft_id%253Dinfo%253Apmid%252F22508308%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYWFjIjtzOjU6InJlc2lkIjtzOjk6IjU2LzcvMzYyMCI7czo0OiJhdG9tIjtzOjQ4OiIvYmlvcnhpdi9lYXJseS8yMDIwLzAxLzMwLzIwMjAuMDEuMjguOTIyOTIyLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
     <li>
      <span class="ref-label">14.</span>
      <a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text" id="ref-14">↵</a>
      <div class="cit ref-cit ref-journal" id="cit-2020.01.28.922922v2.14" data-doi="10.1128/AAC.01474-16">
       <div class="cit-metadata">
        <cite>
         <span class="cit-auth">
          <span class="cit-name-surname">Tsiang</span>
          <span class="cit-name-given-names">M</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Jones</span>
          <span class="cit-name-given-names">GS</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Goldsmith</span>
          <span class="cit-name-given-names">J</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Mulato</span>
          <span class="cit-name-given-names">A</span>
         </span>, 
         <span class="cit-auth">
          <span class="cit-name-surname">Hansen</span>
          <span class="cit-name-given-names">D</span>
         </span>, 
         <span class="cit-etal">et al.</span> (
         <span class="cit-pub-date">2016</span>) 
         <span class="cit-article-title">Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile</span>. 
         <abbr class="cit-jnl-abbrev">Antimicrob Agents Chemother</abbr>
         <span class="cit-vol">60</span>: 
         <span class="cit-fpage">7086</span>–
         <span class="cit-lpage">7097</span>.
        </cite>
       </div>
       <div class="cit-extra">
        <a href="{openurl}?query=rft.jtitle%253DAntimicrob%2BAgents%2BChemother%26rft_id%253Dinfo%253Adoi%252F10.1128%252FAAC.01474-16%26rft_id%253Dinfo%253Apmid%252F27645238%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx" class="cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url">
         <span>OpenUrl</span>
        </a>
        <a href="/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYWFjIjtzOjU6InJlc2lkIjtzOjEwOiI2MC8xMi83MDg2IjtzOjQ6ImF0b20iO3M6NDg6Ii9iaW9yeGl2L2Vhcmx5LzIwMjAvMDEvMzAvMjAyMC4wMS4yOC45MjI5MjIuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9" class="cit-ref-sprinkles cit-ref-sprinkles-ijlink">
         <span>
          <span class="cit-reflinks-abstract">Abstract</span>
          <span class="cit-sep cit-reflinks-variant-name-sep">/</span>
          <span class="cit-reflinks-full-text">
           <span class="free-full-text">FREE </span>Full Text
          </span>
         </span>
        </a>
       </div>
      </div>
     </li>
    </ol>
   </div>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
